Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 2
Submit an article Journal homepage
128
Views
0
CrossRef citations to date
0
Altmetric
Infectious Disease

A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan

Jia-Hung Chena National Health Insurance Administration – Southern Region, Ministry of Health and Welfare, Tainan, Taiwan
,
Pei-Ning Wua National Health Insurance Administration – Southern Region, Ministry of Health and Welfare, Tainan, Taiwan
,
Sin-Chi Huanga National Health Insurance Administration – Southern Region, Ministry of Health and Welfare, Tainan, Taiwan
,
Pao-Ju Hsua National Health Insurance Administration – Southern Region, Ministry of Health and Welfare, Tainan, Taiwan
&
Jason C. Hsub International PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2997-2404
ORCID Icon
Pages 245-252 | Received 26 Jul 2020, Accepted 26 Nov 2020, Published online: 13 Jan 2021

References

  • Chen G-T. Review of new drug management trends in national health insurance over the years. 2014.
  • Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58–S68.
  • Huang WL, Liao YH, Lin YJ, et al. Investigation of transfusion associated hepatitis C virus infection in Taiwan, 2015–2018. J Formos Med Assoc. 2019;119(3):752–756.
  • Chen JJ, Lee PL, Chiu HC, et al. Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan. J Gastroenterol Hepatol. 2019;35(3):467–472.
  • Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C. A nationwide survey in Taiwan. Medicine. 2015;94(13):e690.
  • Chen YY, Chen CL, Chen JW, et al. Secular trends and geographic maps of hepatitis C virus infection among 4 million blood donors in Taiwan from 1999 to 2017. Hepatol Commun. 2020;4(8):1193–1205.
  • Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164–2170.
  • Taiwan Centers for Disease Control. 2017 Statistics of Communicable Diseases and Survillance Report. Taipei: Taiwan Centers for Disease Control; 2018.
  • Chi CT, Chen CY, Su CW, et al. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect. 2019. DOI:10.1016/j.jmii.2019.09.006
  • Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106(2):148–155.
  • National Health Insurance Administration. Hepatitis C full oral new drug health insurance payment implementation plan. Taipei: National Health Insurance Administration; 2017.
  • Li Y, Wang J, Wang J, et al. SVR Rates of HCV-infected population under PEG-IFN-alpha/R treatment in Northwest China. Virol J. 2017;14(1):62.
  • Shiell A, Law MG. The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy. 2001;58:121–131.
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965.
  • Taki S, Tamai H, Ida Y, et al. The real-world safety and efficacy of daclatasvir and asunaprevir for elderly patients. Gut Liver. 2018;12:86–93.
  • Sperl J, Kreidlova M, Merta D, et al. Paritaprevir/ritonavir/ombitasvir plus dasabuvir regimen in the treatment of genotype 1 chronic hepatitis c infection in patients with severe renal impairment and end-stage renal disease: a real-life cohort. Kidney Blood Press Res. 2018;43(2):594–605.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.